Overview

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

Status:
Completed
Trial end date:
2020-11-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of ALLN-346 in healthy volunteers, in this first in human, single ascending dose study. ALLN-346 is an enzyme that degrades urate in the gastrointestinal tract.
Phase:
Phase 1
Details
Lead Sponsor:
Allena Pharmaceuticals
Treatments:
Rasburicase
Uric Acid